Epigenetic regulation in estrogen receptor positive breast cancer-role in treatment response

Journal of Mammary Gland Biology and Neoplasia

Volumn 15, Issue 1, 2010, Pages 35-47

  Pathiraja, Thushangi N ^a   Stearns, Vered ^b   Oesterreich, Steffi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Antiestrogen; Breast cancer; Epigenetics; Estrogen; Tamoxifen

Indexed keywords

4 N ACETYLDINALINE; 5 AZA 2' DEOXYCYTIDINE; AROMATASE INHIBITOR; AZACITIDINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEPSIPEPTIDE; DNA METHYLTRANSFERASE; DOXORUBICIN; ENTINOSTAT; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; LETROZOLE; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PANOBINOSTAT; PROGESTERONE RECEPTOR; SNDX 275; TAMOXIFEN; TRASTUZUMAB; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROATE MAGNESIUM; VORINOSTAT; ZEBULARINE;

ACUTE GRANULOCYTIC LEUKEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RELAPSE; CANCER RESISTANCE; CARDIOTOXICITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DNA METHYLATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIGENETICS; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE CONTROL; GENE EXPRESSION REGULATION; HEMATOLOGIC MALIGNANCY; HUMAN; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PHARMACOGENOMICS; PROGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; SOLID TUMOR; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME;

EID: 77149122714     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10911-010-9166-0     Document Type: Review

References (108)

1. K Altundag NK Ibrahim 2006 Aromatase inhibitors in breast cancer: an overview Oncologist 11 553 62 16794235
2. M Baum 2002 The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment Eur J Cancer 38 1984 6 12376201
3. D Crivellari Z Sun AS Coates, et al. 2008 Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial J Clin Oncol 26 1972 9 18332471
4. N Normanno M Di Maio E De Maio, et al. 2005 Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer Endocr Relat Cancer 12 721 47 16322319
5. EA Musgrove RL Sutherland 2009 Biological determinants of endocrine resistance in breast cancer Nat Rev Cancer 9 631 43 19701242
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 717
7. SR Johnston M Dowsett 2003 Aromatase inhibitors for breast cancer: lessons from the laboratory Nat Rev Cancer 3 821 31 14668813
8. JI MacGregor VC Jordan 1998 Basic guide to the mechanisms of antiestrogen action Pharmacol Rev 50 151 96 9647865
9. VJ Bardou G Arpino RM Elledge CK Osborne GM Clark 2003 Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases J Clin Oncol 21 1973 9 12743151
10. X Cui P Zhang W Deng, et al. 2003 Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer Mol Endocrinol 17 575 88 12554765
11. S Hiscox L Morgan TP Green D Barrow J Gee RI Nicholson 2006 Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells Breast Cancer Res Treat 97 263 74 16333527
12. DJ Britton IR Hutcheson JM Knowlden, et al. 2006 Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth Breast Cancer Res Treat 96 131 46 16261397
13. IR Hutcheson JM Knowlden TA Madden, et al. 2003 Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells Breast Cancer Res Treat 81 81 93 14531500
14. J Shou S Massarweh CK Osborne, et al. 2004 Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer J Natl Cancer Inst 96 926 35 15199112
15. S Masamura SJ Santner DF Heitjan RJ Santen 1995 Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells J Clin Endocrinol Metab 80 2918 25 7559875
16. RJ Santen RX Song Z Zhang, et al. 2003 Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention Endocr Relat Cancer 10 111 30 12790774
17. LA Martin I Farmer SR Johnston S Ali M Dowsett 2005 Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation Endocr Relat Cancer 12 Suppl 1 S75 84 16113101
18. AM Redmond FT Bane AT Stafford, et al. 2009 Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence Clin Cancer Res 15 2098 106 19276281
19. CK Osborne V Bardou TA Hopp, et al. 2003 Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer J Natl Cancer Inst 95 353 61 12618500
20. I Girault F Lerebours S Amarir, et al. 2003 Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen Clin Cancer Res 9 1259 66 12684393
21. S Bautista H Valles RL Walker, et al. 1998 In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity Clin Cancer Res 4 2925 9 9865902
22. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 82 3798106
23. RB Riggins RS Schrecengost MS Guerrero AH Bouton 2007 Pathways to tamoxifen resistance Cancer Lett 256 1 24 17475399
24. G Arpino L Wiechmann CK Osborne R Schiff 2008 Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance Endocr Rev 29 217 33 18216219
25. K Pruitt RL Zinn JE Ohm, et al. 2006 Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation PLoS Genet 2 e40 16596166
26. PA Jones SB Baylin 2007 The epigenomics of cancer Cell 128 683 92 17320506
27. HD Morgan F Santos K Green W Dean W Reik 2005 Epigenetic reprogramming in mammals Hum Mol Genet 14 Spec No 1 R47 58 15809273
28. SL Berger 2007 The complex language of chromatin regulation during transcription Nature 447 407 12 17522673
29. KN Harikrishnan MZ Chow EK Baker, et al. 2005 Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing Nat Genet 37 254 64 15696166
30. PL Jones GJ Veenstra PA Wade, et al. 1998 Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription Nat Genet 19 187 91 9620779
31. X Nan HH Ng CA Johnson, et al. 1998 Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex Nature 393 386 9 9620804
32. PA Jones SB Baylin 2002 The fundamental role of epigenetic events in cancer Nat Rev Genet 3 415 28 12042769
33. AP Feinberg B Tycko 2004 The history of cancer epigenetics Nat Rev Cancer 4 143 53 14732866
34. M Widschwendter PA Jones 2002 DNA methylation and breast carcinogenesis Oncogene 21 5462 82 12154408
35. R Radpour C Kohler MM Haghighi AX Fan W Holzgreve XY Zhong 2009 Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array Oncogene 28 2969 78 19503099
36. SR Romanov BK Kozakiewicz CR Holst MR Stampfer LM Haupt TD Tlsty 2001 Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes Nature 409 633 7 11214324
37. TD Tlsty SR Romanov BK Kozakiewicz CR Holst LM Haupt YG Crawford 2001 Loss of chromosomal integrity in human mammary epithelial cells subsequent to escape from senescence J Mammary Gland Biol Neoplasia 6 235 43 11501583
38. AR Mistry EW Pedersen E Solomon D Grimwade 2003 The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease Blood Rev 17 71 97 12642121
39. S Varambally SM Dhanasekaran M Zhou, et al. 2002 The polycomb group protein EZH2 is involved in progression of prostate cancer Nature 419 624 9 12374981
40. AM Pietersen HM Horlings M Hauptmann, et al. 2008 EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer Breast Cancer Res 10 R109 19099573
41. CG Kleer Q Cao S Varambally, et al. 2003 EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells Proc Natl Acad Sci USA 100 11606 11 14500907
42. PA Reynolds M Sigaroudinia G Zardo, et al. 2006 Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells J Biol Chem 281 24790 802 16766534
43. X Li ME Gonzalez K Toy T Filzen SD Merajver CG Kleer 2009 Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia Am J Pathol 175 3 1246 54 19661437
44. SE Elsheikh AR Green EA Rakha, et al. 2009 Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome Cancer Res 69 3802 9 19366799
45. S Pfister S Rea M Taipale, et al. 2008 The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma Int J Cancer 122 1207 13 18058815
46. YL Ottaviano JP Issa FF Parl HS Smith SB Baylin NE Davidson 1994 Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells Cancer Res 54 2552 5 8168078
47. T Sogon S Masamura S Hayashi RJ Santen K Nakachi H Eguchi 2007 Demethylation of promoter C region of estrogen receptor alpha gene is correlated with its enhanced expression in estrogen-ablation resistant MCF-7 cells J Steroid Biochem Mol Biol 105 106 14 17574841
48. L Yan SJ Nass D Smith WG Nelson JG Herman NE Davidson 2003 Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines Cancer Biol Ther 2 552 6 14614325
49. MR Rountree KE Bachman SB Baylin 2000 DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci Nat Genet 25 269 77 10888872
50. X Yang DL Phillips AT Ferguson WG Nelson JG Herman NE Davidson 2001 Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells Cancer Res 61 7025 9 11585728
51. JC Keen L Yan KM Mack, et al. 2003 A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine Breast Cancer Res Treat 81 177 86 14620913
52. Q Zhou P Atadja NE Davidson 2007 Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation Cancer Biol Ther 6 64 9 17172825
53. L Fleury M Gerus AC Lavigne H Richard-Foy K Bystricky 2008 Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells Oncogene 27 4075 85 18317449
54. M Billam MD Sobolewski NE Davidson 2009 Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells Breast Cancer Res Treat 21 1573 7217 Electronic
55. L Tung H Abdel-Hafiz T Shen, et al. 2006 Progesterone receptors (PR)-B and -A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B Mol Endocrinol 20 2656 70 16762974
56. TA Hopp HL Weiss SG Hilsenbeck, et al. 2004 Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates Clin Cancer Res 10 2751 60 15102680
57. P Parrella ML Poeta AP Gallo, et al. 2004 Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors Clin Cancer Res 10 5349 54 15328171
58. E Sunami M Shinozaki MS Sim, et al. 2008 Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors Breast Cancer Res 10 R46 18485221
59. KP Suijkerbuijk MJ Fackler S Sukumar, et al. 2008 Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer Ann Oncol 19 1870 4 18647968
60. M Widschwendter KD Siegmund HM Muller, et al. 2004 Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen Cancer Res 64 3807 13 15172987
61. HG Chang SJ Kim KW Chung, et al. 2005 Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene J Mol Med 83 132 9 15536519
62. JW Martens I Nimmrich T Koenig, et al. 2005 Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer Cancer Res 65 4101 17 15899800
63. D Sharma NK Saxena NE Davidson PM Vertino 2006 Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes Cancer Res 66 6370 8 16778215
64. J Fan WJ Yin JS Lu, et al. 2008 ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor J Cancer Res Clin Oncol 134 883 90 18264725
65. Sabnis GJ, Goloubeva O, Gilani R, et al. Expression of ER and aromatase in MDA-MB-231 tunors by HDAC inhibitor entinostat leads to growth inhibition by aromatase inhibitor letrozole. San Antonio Breast Cancer Symposium (abstract) 2009.
66. H Fiegl S Millinger G Goebel, et al. 2006 Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer Cancer Res 66 29 33 16397211
67. E Badia MJ Duchesne A Semlali, et al. 2000 Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling Cancer Res 60 4130 8 10945620
68. J Oliva S El Messaoudi F Pellestor, et al. 2005 Involvement of HP1alpha protein in irreversible transcriptional inactivation by antiestrogens in breast cancer cells FEBS Lett 579 4278 86 16051232
69. S Oesterreich P Zhang RL Guler, et al. 2001 Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth Cancer Res 61 5771 7 11479214
70. YW Leu PS Yan M Fan, et al. 2004 Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer Cancer Res 64 8184 92 15548683
71. M Fan PS Yan C Hartman-Frey, et al. 2006 Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant Cancer Res 66 11954 66 17178894
72. MP Goetz VJ Suman FJ Couch, et al. 2008 Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance Clin Cancer Res 14 5864 8 18794098
73. MP Jansen AM Sieuwerts MP Look, et al. 2007 HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study J Clin Oncol 25 662 8 17308270
74. BA Rodriguez AS Cheng PS Yan, et al. 2008 Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer Carcinogenesis 29 1459 65 18499701
75. E Iorns NC Turner R Elliott, et al. 2008 Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer Cancer Cell 13 91 104 18242510
76. G Heller B Ziegler A Brandstetter, et al. 2009 CDK10 is not a target for aberrant DNA methylation in breast cancer Anticancer Res 29 3939 44 19846932
77. S Maier I Nimmrich T Koenig, et al. 2007 DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients-Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group Eur J Cancer 43 1679 86 17601725
78. N Harbeck I Nimmrich A Hartmann, et al. 2008 Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients J Clin Oncol 26 5036 42 18711169
79. SA Leon B Shapiro DM Sklaroff MJ Yaros 1977 Free DNA in the serum of cancer patients and the effect of therapy Cancer Res 37 646 50 837366
80. S Gal C Fidler YM Lo, et al. 2004 Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR Br J Cancer 90 1211 5 15026803
81. I Van der Auwera HJ Elst SJ Van Laere, et al. 2009 The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients Br J Cancer 100 1277 86 19367284
82. E Dulaimi J Hillinck I Ibanez de Caceres T Al-Saleem P Cairns 2004 Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients Clin Cancer Res 10 6189 93 15448006
83. HM Muller A Widschwendter H Fiegl, et al. 2003 DNA methylation in serum of breast cancer patients: an independent prognostic marker Cancer Res 63 7641 5 14633683
84. J Martinez-Galan B Torres R Del Moral, et al. 2008 Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy Cancer Biol Ther 7 958 65 18379196
85. H Fiegl S Millinger E Mueller-Holzner, et al. 2005 Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients Cancer Res 65 1141 5 15734995
86. A Aparicio B North L Barske, et al. 2009 LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors Epigenetics 4 176 84 19421002
87. V Stearns Q Zhou NE Davidson 2007 Epigenetic regulation as a new target for breast cancer therapy Cancer Invest 25 659 65 18058459
88. JP Issa HM Kantarjian 2009 Targeting DNA methylation Clin Cancer Res 15 3938 46 19509174
89. HM Kantarjian S O'Brien X Huang, et al. 2007 Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience Cancer 109 1133 7 17315156
90. TH Luu RJ Morgan L Leong, et al. 2008 A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study Clin Cancer Res 14 7138 42 18981013
91. A Stathis S Hotte H Hirte, et al. 2009 Phase I study of intravenous decitabine in combination with oral vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas (NHL) J Clin Oncol 27 15s suppl; abstr 3528
92. C Arce C Perez-Plasencia A Gonzalez-Fierro, et al. 2006 A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer PLoS ONE 1 e98 17183730
93. M Candelaria D Gallardo-Rincon C Arce, et al. 2007 A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors Ann Oncol 18 1529 38 17761710
94. Ramaswamy B, Bhalla K, Cohen B, et al. Phase II study of the histone deacetylase inhibitor (HDACi) vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer (MBC): New York Cancer consortium trial P7703. AACR 100th Annual Meeting April 18-22, 09-AB4116-AACR Denver, CO 2009.
95. P Munster M Lacevic S Thomas, et al. 2009 Phase II trial of the histone deacetylase inhibitor, vorinostat, to restore hormone sensitivity to the antiestrogen tamoxifen in patients with advanced breast cancer who progressed on prior hormone therapy J Clin Oncol, ASCO Annual Meeting Proceedings 27 1075
96. RG Lapidus AT Ferguson YL Ottaviano, et al. 1996 Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors Clin Cancer Res 2 805 10 9816234
97. NS Falette SA Fuqua GC Chamness MS Cheah GL Greene WL McGuire 1990 Estrogen receptor gene methylation in human breast tumors Cancer Res 50 3974 8 2354445
98. RG Lapidus SJ Nass KA Butash, et al. 1998 Mapping of ER gene CpG island methylation-specific polymerase chain reaction Cancer Res 58 2515 9 9635570
99. H Iwase Y Omoto H Iwata, et al. 1999 DNA methylation analysis at distal and proximal promoter regions of the oestrogen receptor gene in breast cancers Br J Cancer 80 1982 6 10471050
100. S Mirza G Sharma CP Prasad, et al. 2007 Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients Life Sci 81 280 7 17599361
101. W Feng L Shen S Wen, et al. 2007 Correlation between CpG methylation profiles and hormone receptor status in breast cancers Breast Cancer Res 9 R57 17764565
102. M Wei J Xu J Dignam, et al. 2008 Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers Breast Cancer Res Treat 111 113 20 17932744
103. S Li M Rong B Iacopetta 2006 DNA hypermethylation in breast cancer and its association with clinicopathological features Cancer Lett 237 272 80 16029926
104. WB Archey KA McEachern M Robson, et al. 2002 Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers Oncogene 21 7034 41 12370825
105. SJ Nass JG Herman E Gabrielson, et al. 2000 Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer Cancer Res 60 4346 8 10969774
106. O Mc Cormack WY Chung P Fitzpatrick, et al. 2008 Progesterone receptor B (PRB) promoter hypermethylation in sporadic breast cancer: progesterone receptor B hypermethylation in breast cancer Breast Cancer Res Treat 111 45 53 17896177
107. http://clinicaltrials.gov.
108. Stearns V, Jacobs LK, Tsangaris TN, et al. A pilot study evaluating surrogates of response to short-term vorinostat in women with newly diagnosed breast cancer. J Clin Oncol 27 suppl; abstr e14508 2009; ASCO Annual Meeting.